12:00 AM
 | 
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Concert Pharmaceuticals preclinical data

In in vitro efficacy assays, CTP-221 produced a 2.7-fold increase in IL-2 induction in anti-CD3 stimulated peripheral blood mononuclear cells (PBMCs) compared to racemic lenalidomide. Additionally, CTP-221 produced a 3.7-fold greater inhibition of tumor necrosis...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >